Fraser Murray

Fraser Murray is a seasoned biotechnology executive with extensive experience in scientific evaluation, strategic leadership, and company formation within the life sciences sector. Currently serving as Chief Executive Officer and Investor Director at Pheno Therapeutics Ltd, Fraser focuses on developing therapeutics for remyelination. As Head of Scientific Evaluation at Advent Life Sciences, Fraser plays a key role in venture investments across the UK, Europe, and the USA. Additionally, Fraser co-founded Pandeia Therapeutics, contributing to its development of GPR88 agonists and supporting its acquisition in 2022. Ongoing advisory roles at Chronos Therapeutics and Woodyett Consulting further showcase Fraser's commitment to advancing innovative solutions in neurodegenerative diseases and other medical fields. Fraser holds an MBA with Distinction from Alliance Manchester Business School, a PhD in Neuroscience from The School of Pharmacy, University of London, and a BSc in Immunology and Pharmacology from the University of Strathclyde.